|| List of recent Erythropoietin-related patents
|Novel tissue protective erythropoietin receptor (nepor) and methods of use|
Methods of determining whether a patient is suitable for erythropoietin (epo) therapy, including (a) isolating a tissue sample from said patient; (b) determining the level of expression of eph-b4 in said sample; and (c) correlating a presence of eph-b4 expression to a negative physiological response to epo therapy). In addition, methods of enhancing the effectiveness of epo therapy in a patient by administering to said patient, in conjunction with epo therapy, an sirna specific for eph-b4..
|Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell|
A composition for inducing erythropoietin (epo)-mediated haemoglobin (hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (i), wherein r is a glycosyl group; and a pharmaceutical acceptable carrier..
|Erythropoietin production-promoting agent|
A therapeutic and/or prophylactic agent for renal anemia comprising alas and an erythropoietin production promoter comprising alas.. .
|Methods of treating cognitive impairment|
The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible transcription factor (hif-1alpha), insulin like growth factor-1 (igf-1), tumor necrosis factor (tnf), granulocyte colony-stimulating factor (g-csf), granulocyte/macrophage colony-stimulating factor (gm-csf), macrophage colony-stimulating factor (m-csf), stem cell factor (scf), darbepoetin (aranesp), and metalloproteinases, to an animal or person in need of treatment..
|Methods for purifying erythropoietin analogs having lower isoelectric point|
The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an n-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost..
|Use of hematopoietic growth factor mimetics|
The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin..
|Erythropoietin receptor modified electrode and its preparation method and application|
The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via zno sol-gel. The modified electrode can be prepared easily, and its performance is stable.
|Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens|
Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins.
|Use of il-12 to generate endogenous erythropoietin|
The present invention relates to the use of exogenous interleukin-12 (il-12) for increasing endogenous production of erythropoietin.. .
|Method for purifying pegylated erythropoietin|
Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange sp sephacryl™ s 500 hr chromatography material conditioned to a conductivity of 21 ms/cm and a linear gradient elution a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield..
|Tetrameric cytokines with improved biological activity|
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
|Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications|
A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject.
|Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival|
Disclosed herein are erythropoietin-mimetic compounds of formula i, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor.
|Treatment and prevention of diseases related to oxidative stress|
The present invention relates to the field of treatment and prevention of conditions related to oxidative stress and hormone resistance. Preferably, insulin resistance, erythropoietin resistance and acetyl-choline resistance are in the focus.
|Compositions and methods for preventing erythropoietin-associated hypertension|
The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (epo) to the mammal; and administering to the mammal an agent selected from a soluble epo-binding protein (epo-bp), a recognition protein that binds epo receptor on an extracellular soluble portion of the epo receptor, and a combination thereof.
|Epo knockout gfp anemic mouse|
The present invention relates to a model animal spontaneously developing anemia. More specifically, the invention relates to a transgenic non-human mammal spontaneously developing anemia associated with a postnatal decrease in production of erythropoietin (epo), epo-producing cells prepared from the transgenic non-human mammal, and a screening method using the epo-producing cells..
|Composition for aiding surgical procedures for treating ischemic vascular diseases|
The present invention relates to a composition comprising erythropoietin (epo) as an active ingredient for aiding surgical procedures for treating ischemic vascular diseases. The present invention also relates to a method for treating ischemic vascular diseases using said composition.
|Compositions and methods for increasing erythropoietin (epo) production|
The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting one or more egln genes, egln1, egln2 and/or egln3 and methods of using such dsrna compositions to inhibit expression of these genes.. .
|Encapsulated liver cell composition|
Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin.. .
|Modified animal erythropoietin polypeptides and their uses|
Modified animal erythropoietin polypeptides and uses thereof are provided.. .
|Therapeutic compositions and methods for disorders associated with neuronal degeneration|
Disclosed are isolated mutant erythropoietin (epo) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant epo peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76.
|Composition for promoting hematogenesis containing quercetin 3-o-beta-(2''-galloyl)-rhamnopyranoside as active ingredient|
This invention relates to a composition for promoting hematopoiesis and for treating, preventing or alleviating cytopenia or bone marrow failure comprising quercetin 3-o-β-(2″-galloyl)-rhamnopyranoside (qgr) as active ingredient. The present active compound qgr (i) increases dose dependently the mrna expression of cytokines involved in hematopoiesis including stem cell factor, granulocyte-macrophage colony stimulating factor and erythropoietin from mouse bone marrow mononuclear cells, (ii) promotes the formation of burst forming unit-erythroid and colony forming unit-fibroblast, (iii) stimulates the generation of cells positive for ter-119, a specific marker of mouse erythroid precursors, (iv) promotes erythropoiesis, leukopoiesis, thrombopoiesis, and hemoglobin production in bone marrow failure mouse model, (v) stimulates the formation of hematopoietic stem/progenitor cells and mesenchymal stem/progenitor cells, (vi) stimulates megakaryocyte formation surrounding the blood system of damaged bone marrow, osteoid formation and bone marrow restoration through a recovery of damaged bone marrow microenvironment.
|Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer|
Nucleic acids encoding erythropoietin isoforms are described herein, as well as the encoded isoforms, methods of detecting the same, and methods of screening for and treating cancer.. .
|Method of treating anemia caused by ribavirin treatment of hepatitis c using erythropoietin alpha|
Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using erythropoetin to treat anemia caused by the combined treatment of ribavirin and alpha-interferon.
|Homogenous and fully glycosylated human erythropoietin|
The present invention provides homogenous, fully-glycosylated, full length erythropoietin and the methods of producing the same.. .
|Compounds and methods for enhancing erythropoiesis|
Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (i) indicated below, in which r is a glucosyl group.
|Novel nitrogen-containing heteroaryl compounds and methods of use thereof|
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.. .
The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies..
|Treatment of acute ischemic stroke or intracranial bleeding with tpa and carbamylated erythropoietin|
The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tpa and a therapeutically effective amount of carbamylated erythropoietin.. .
|Long lasting drug formulations|
The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.. .
|Novel peptides that bind to the erythropoietin receptor|
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (epo-r). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production.
|Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure|
The invention relates to an in-vitro and in-vivo method for multiplying and differentiating cells, during which the growth process of the cells is initiated or terminated and structurally directed by the use of growth factors thrombopoietin (tpo) and/or erythropoietin (epo), and/or growth hormone (gh), particularly human growth hormone (hgh), and/or somatostatin and/or leukemia inhibitory factor (lif) and/or ciliary neurotropic factor (cntf). The invention also relates to a biological matrix or supporting structure containing the aforementioned growth factors, and to a method and device for the production thereof and for carrying out the inventive method..
|Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo|
A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin.